It's been a wild ride for investors in Telix Pharmaceuticals Ltd (ASX: TLX) shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of writing.
That kind of volatility might scare some investors away. But for others, it raises a more intriguing question: Could Telix shares become a long-term winner and turn $50,000 into a $1,000,000?
Image source: Getty Images
A different growth story
Telix isn't your typical early-stage biotech. The company develops radiopharmaceuticals used in cancer diagnosis and treatment. It operates in a niche combining precision medicine with complex manufacturing and global distribution.
Importantly, Telix has already transitioned into full commercial operations. That sets it apart from many speculative biotech plays still waiting on approvals.
As more of its products gain regulatory clearance and clinical adoption increases, revenue has the potential to scale rapidly. In other words, future growth is less about macroeconomic conditions and more about how quickly its therapies are adopted.
That dynamic can create sharp price swings, as seen recently with Telix shares. But it also offers direct exposure to a high-growth corner of healthcare.
Revenue is booming
Telix's latest results show just how quickly the business is expanding.
Last month, the company reported full-year revenue of US$803 million, up 56% year on year and at the lower end of its upgraded guidance range.
Even more impressive, it expects to generate between US$950 million and US$970 million in revenue this year. That would push it comfortably beyond the $1 billion mark.
At the same time, Telix is continuing to invest heavily in future growth, with research and development spending forecast at US$200 million to US$240 million.
This combination of strong revenue growth and continued innovation is exactly what long-term investors in Telix shares want to see.
Major opportunity, limited competition
One of the most exciting developments is Telix's progress in brain cancer.
The company recently submitted a European marketing application for TLX101-Px, an imaging agent designed for glioblastoma — one of the most aggressive and difficult-to-treat cancers.
This week, Telix resubmitted its New Drug Application to the U.S. FDA for TLX101-Px, including new data addressing prior feedback and supporting approval.
Crucially, there are currently no widely available commercial alternatives. That gives Telix a rare opportunity to address an urgent medical need with limited direct competition.
If successful, this could become a meaningful growth driver for Telix shares in the years ahead.
What do analysts think?
Despite the share price slump, sentiment remains overwhelmingly positive on Telix shares.
According to TradingView data, all 16 analysts covering ASX biotech stock rate it as a buy or strong buy. Average 12-month price targets suggest Telix shares could climb around 95% to $23.97, with the most bullish forecasts pointing to as high as $31.59. This points to a potential upside of more than 150%.
That's a remarkable level of confidence for a stock that has fallen so sharply.
Foolish Takeaway
There's no doubt Telix shares carry risk. Biotech stocks are inherently volatile, and success depends on execution, approvals, and market uptake.
But with surging revenues, a growing commercial footprint, and exposure to a high-value medical niche, Telix has the ingredients of a powerful long-term growth story.
If it can deliver on its pipeline and scale globally, today's weakness could one day look like an opportunity. The kind that patient investors have million-dollar dreams about.
